Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISAL 2019 | Frontline FLAG-Ida for high-risk AML: data from the UK NCRI AML17 trial

Alan Burnett • 1 Mar 2019
ISAL 2019
Acute Myeloid Leukemia Leukemia Clofarabine Daunorubicin
AML17

“The UK NCRI AML17 trial (ISRCTN55675535) investigated a number of interventions for younger patients with acute myeloid leukemia (AML). We spoke to Alan Burnett, MD, FRCP, of Cardiff University, Cardiff, UK, about the results of the comparison of FLAG-Ida and daunorubicin with clofarabine for high-risk AML in the trial, which were recently published. This interview took place at the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany.

https://www.ncbi.nlm.nih.gov/pubmed/29875430”

More from Alan Burnett

2:32
ISAL session highlights: gemtuzumab & small molecule inhibitors with chemotherapy in AML and APL
Alan Burnett • 21 Mar 2023
3:14
Standard treatment of elderly patients with AML & evaluating IDH inhibitors in younger patients
Alan Burnett • 21 Mar 2023
11:06
The future treatment of acute leukemias: part I
Alan Burnett et al. • 18 Jun 2019
19:48
The future treatment of acute leukemias: part II
Alan Burnett et al. • 18 Jun 2019

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals